CD274 and cervical carcinoma: Immune checkpoint inhibitors (ICIs) have transformed oncology by enhancing T-cell-mediated anti-tumor responses, and their application in cervical cancer has led to regulatory approval of pembrolizumab for PD-L1-positive advanced cases, based on results from KEYNOTE-158 [5,22].